In addition to differences in eGFRcreat between NT-proBNP subgroups, although patients with secondary hypertension were excluded, the possibility of including a certain number of patients with primary aldosteronism cannot be ruled out because a definitive diagnosis of primary aldosteronism was not required. This evidence concerns the gene NPPB and secondary hypertension.